| Title | [Efficacy and Safety of High-dose Toremifene for Hormone-responsive Advanced or Metastatic Breast Cancer Patients with Failed Prior Treatment by Aromatase Inhibitors.] | | Author(s) | Ohtake T, Yasuda M, Watanabe K, Ito T, Ito J, Miyamoto K, Yoshida S, Abe N, Ishigame T, Ishii M, Kimijima I, Takenoshita S | | Institution | Dept. of Surgery, Fukushima Medical University School of Medicine. | | Source | Gan To Kagaku Ryoho 2009 Sep; 36(9):1459-63. | | Abstract | Background: Recently, aromatase inhibitors(AI)are widely used in postoperative adjuvant therapy for breast cancer. Nevertheless, studies of postoperative therapeutic strategies for recurrent breast cancer are insufficient. Subjects and method: Data on 12 post-menopausal advanced/recurrent breast cancer patients in our department during June 2003- April 2007 were used for this study. No patient had responded to high-dose toremifene(TOR), a third-generation AI. Their therapeutic outcomes were analyzed retrospectively. The median observation period of the subjects was 16.1 months(4.0-40.9 months). Subjects were all hormone-sensitive. Overexpression of HER2 protein was found in only one case. During AI therapy immediately prior, exemestane(EXE)and anastrozole(ANA)had been given in nine and three cases, respectively.
Results: The complete response rate of AI therapy was 16.7%(2/12). The clinical benefit rate was 58.3%(7/12). The median of time to progression(TTP)was 33.8 weeks. Neither the presence nor absence of past history of treatment with tamoxifen(TAM)or other chemotherapies affected the anti-tumor effect. Analysis by the site of metastasis or recurrence revealed that the therapeutic effects were better for non-life-threatening cases in the lung, pleura, soft tissue, etc. The severities of adverse effects were all less than grade 2; the major ones were flushing and sweating.
Conclusion: Results show that high-dose TOR given at an early stage can provide clinical benefits for post-menopausal advanced/recurrent breast cancer not responding to AI. | | Language | jpn | | Pub Type(s) | English Abstract
Journal Article
| | PubMed ID | 19755813 |
|
